

# Peter G Maslak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8114411/publications.pdf>

Version: 2024-02-01

63  
papers

11,016  
citations

172207

29  
h-index

149479

56  
g-index

63  
all docs

63  
docs citations

63  
times ranked

11999  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies. <i>Cancer Discovery</i> , 2022, 12, 62-73.	7.7	65
2	Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. <i>Blood</i> , 2022, 139, 2758-2769.	0.6	25
3	Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. <i>Clinical Cancer Research</i> , 2022, 28, 2030-2037.	3.2	21
4	A simplified CD34 <sup>+</sup> based preharvest prediction tool for HPC(A) collection. <i>Transfusion</i> , 2021, 61, 1525-1532.	0.8	1
5	Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. <i>Blood</i> , 2021, 138, 531-543.	0.6	42
6	CD8 <sup>+</sup> T cells contribute to survival in patients with COVID-19 and hematologic cancer. <i>Nature Medicine</i> , 2021, 27, 1280-1289.	15.2	365
7	Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 697.e1-697.e5.	0.6	7
8	Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 2086-2094.	1.7	24
9	Evaluation of peripheral blood mononuclear cell collection by leukapheresis. <i>Transfusion</i> , 2019, 59, 1765-1772.	0.8	15
10	Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 449-459.	13.9	1,951
11	Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 224-234.	2.5	124
12	Method comparison study of peripheral blood CD34 <sup>+</sup> count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified) <i>Tj ETQq0 0 0 rgBT / Overlock 20 Tf 50 29</i>		
13	Comparison of manual hematocrit determinations versus automated methods for hematopoietic progenitor cell apheresis products. <i>Transfusion</i> , 2016, 56, 528-532.	0.8	11
14	Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma. <i>American Journal of Clinical Pathology</i> , 2016, 146, 41-49.	0.4	37
15	Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow. <i>Journal of Hematopathology</i> , 2016, 9, 9-18.	0.2	6
16	Evaluation of new automated hematopoietic progenitor cell analysis in the clinical management of peripheral blood stem cell collections. <i>Transfusion</i> , 2015, 55, 2001-2009.	0.8	25
17	Using the Hemoglobin Content of Reticulocytes (RET-He) to Evaluate Anemia in Patients With Cancer. <i>American Journal of Clinical Pathology</i> , 2014, 142, 506-512.	0.4	24
18	Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. <i>Science Translational Medicine</i> , 2014, 6, 224ra25.	5.8	2,069

#	ARTICLE	IF	CITATIONS
19	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 1226-1231.	9.4	270
20	Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. <i>Leukemia Research</i> , 2013, 37, 32-36.	0.4	29
21	Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?. <i>Cancer</i> , 2013, 119, 1186-1194.	2.0	16
22	CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. <i>Science Translational Medicine</i> , 2013, 5, 177ra38.	5.8	1,748
23	Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody. <i>Science Translational Medicine</i> , 2013, 5, 176ra33.	5.8	147
24	Comparison of Automated Platelet Counts and Potential Effect on Transfusion Decisions in Cancer Patients. <i>American Journal of Clinical Pathology</i> , 2013, 140, 747-754.	0.4	8
25	Translocation t(11;17) in de novo Myelodysplastic Syndrome Not Associated with Acute Myeloid or Acute Promyelocytic Leukemia. <i>Acta Haematologica</i> , 2013, 129, 48-54.	0.7	2
26	Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related?. <i>Blood</i> , 2013, 122, 2740-2740.	0.6	1
27	Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant. <i>Blood</i> , 2013, 122, 4647-4647.	0.6	0
28	Potential Clinical Impact of Inaccurate Automated Platelet Counts in the Setting of Severe Thrombocytopenia. <i>Blood</i> , 2012, 120, 3428-3428.	0.6	1
29	Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR). <i>Blood</i> , 2012, 120, 3624-3624.	0.6	1
30	Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2482-2482.	0.6	1
31	High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012, 120, 4293-4293.	0.6	0
32	Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. <i>Blood</i> , 2011, 118, 4817-4828.	0.6	1,135
33	Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 280-317.	2.3	56
34	Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History. <i>Blood</i> , 2011, 118, 1765-1765.	0.6	0
35	Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center. <i>Blood</i> , 2011, 118, 4433-4433.	0.6	0
36	Translocation t(11;17) Is Not Always Associated with Acute Myeloid or Acute Promyelocytic Leukemia. <i>Blood</i> , 2011, 118, 5044-5044.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. <i>Blood</i> , 2010, 116, 171-179.	0.6	136
38	WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1467-1479.	2.0	108
39	Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses. <i>Journal of Clinical Oncology</i> , 2009, 27, 491-497.	0.8	66
40	Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2008, 14, 826-832.	3.2	126
41	Azacitidine and the beginnings of therapeutic epigenetic modulation. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1981-1986.	0.9	22
42	CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. <i>Blood</i> , 2008, 111, 3403-3406.	0.6	37
43	Strategy for Incorporating Molecular and Cytogenetic Markers into Acute Myeloid Leukemia Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 995-1002.	2.3	2
44	Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells. <i>Clinical Cancer Research</i> , 2007, 13, 4547-4555.	3.2	94
45	Diagnosis and treatment of acute promyelocytic leukemia. <i>Current Oncology Reports</i> , 2007, 9, 337-344.	1.8	36
46	Grading follicular lymphomas in fine-needle aspiration biopsies. <i>Cancer</i> , 2006, 108, 319-323.	2.0	29
47	Antibody-drug conjugates in acute myeloid leukemia. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 238-239.	4.3	2
48	Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, 1575-1581.	0.8	146
49	Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?. <i>Leukemia and Lymphoma</i> , 2006, 47, 1260-1264.	0.6	16
50	CD4+ Peptide Epitopes from the WT1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Leukemia and Solid Tumor Cells.. <i>Blood</i> , 2006, 108, 3706-3706.	0.6	0
51	Therapy of Acute Promyelocytic Leukemia. <i>Advances in Pharmacology</i> , 2004, 51, 35-58.	1.2	4
52	Refractory <i>Aspergillus</i> pneumonia in patients with acute leukemia. <i>Cancer</i> , 2003, 97, 1025-1032.	2.0	234
53	Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 1278-1284.	0.8	100
54	Clinical applications of molecular monitoring in leukemia. <i>Psychophysiology</i> , 2003, 2, 43-8.	1.1	1

#	ARTICLE	IF	CITATIONS
55	Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2002, 20, 2157-2170.	0.8	157
56	A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2002, 95, 581-587.	2.0	32
57	Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 1985-1992.	0.8	198
58	Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. <i>Blood</i> , 2001, 97, 1929-1936.	0.6	25
59	Acute myeloid leukemia with t(5;18)(q35;q21). <i>Cancer Genetics and Cytogenetics</i> , 2001, 127, 71-73.	1.0	5
60	Targeted therapies for the myeloid leukaemias. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1197-1205.	1.9	15
61	Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide. <i>New England Journal of Medicine</i> , 1998, 339, 1341-1348.	13.9	1,149
62	Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia. , 1996, 51, 117-121.		9
63	Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. <i>Cytometry</i> , 1994, 17, 84-93.	1.8	38